Record Point is an independent corporate advisory firm specialising in domestic and international advisory services for public and private companies.
“We were highly impressed with the Record Point team’s lead role during the … sale. The team assisted us by providing the high quality deliverables and process management we have come to expect from advisors, but differentiated themselves through their considered insights and genuinely value-additive approach to M&A. First class execution in every respect.”
“Record Point were instrumental in the … sale process, adding value at every step through to the finish line. The ultimate transaction result that was delivered was far beyond our expectations and would not have been achieved without the dedication and diligence that the Record Point team demonstrated throughout the process.”
“What distinguishes [Record Point] is their clarity of communication, agility, candour, integrity, ability to align the interests of stakeholders and the tremendous informal support they provide to the team during a high value and large scale process.”
“Record Point added value to every step of the process providing my Board and me with commercial and pragmatic advice at all times.“
“Record Point was instrumental in assisting my management team and me on Project Mason. They are an exceptionally capable and professional team who were across the detail of all aspects of the deal.”
“We felt we were in safe and experienced hands throughout the sale processes and with Record Point managing the sale processes, we could continue to operate our business through to completion ensuring we hit our forecasts that potential acquirers were relying on.”
“In addition to enhancing the valuation of the offer, [Record Point] added a tremendous amount of value by assisting me and my team through the challenges of juggling running a business and executing a complex transaction…”
On 26 November 2015, the majority shareholders of Clifford Hallam Healthcare (“CH2”), ASX-listed Australian Pharmaceutical Industries Limited (“API”) and Allegro Funds (“Allegro”) announced that they had entered into an agreement to sell their shareholdings in the Company.
CH2 is Australia’s largest integrated distributor of pharmaceutical and medical consumable products to the domestic healthcare market. The Company supplies more than 50,000 products to over 20,000 customers, operating across four core business units: Hospitals, Aged Care & Community, Primary Care and Veterinary.
API and Allegro’s shareholdings have been acquired by two former CH2 CEOs and long-term shareholders who are experienced healthcare executives with a deep understanding of CH2’s business model, its customers, suppliers and capabilities.
The sale completed on 1 December 2015.
Record Point acted as the exclusive financial advisor to CH2.